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¤¤
¤¤
¤ Background: In recent years, laboratory and clinical
research has suggested the need for peritoneal dialysis flu-
ids (PDFs) that are more biocompatible than the conven-
tional PDFs commonly used today. Bioincompatibility of PDF
has been attributed to low pH, lactate, glucose, glucose
degradation products (GDPs), and osmolality. PDFs with
neutral pH and low GDPs are now available commercially.
In vitro and early clinical studies suggest that these solu-
tions are indeed more biocompatible but, as of now, there
is no evidence that their use improves patient outcome.
¤¤
¤¤
¤ Methods: Using a dedicated database of over 2000 pa-
tients treated with PD in Korea, we were able to conduct a
retrospective observational study comparing outcomes for
incident continuous ambulatory PD patients treated with a
standard, conventional, heat-sterilized PDF to the outcomes
for patients treated with a novel, low GDP, neutral-pH PDF
prepared in a dual-compartment, double-bag PD system
(Balance; Fresenius Medical Care, St. Wendel, Germany). In
an intention-to-treat analysis, patient and technique sur-
vival, peritonitis-free survival, and peritonitis rates were
compared in 611 patients treated with Balance for up to
30 months and 551 patients with a standard PDF (stay·safe;
Fresenius Medical Care) treated in the same era and with
equivalent follow-up.
¤¤
¤¤
¤ Results: The patients were well matched for most relevant
characteristics except older age distribution for the patients
treated with the standard PDF. Patients treated with Bal-
ance had significantly superior survival compared to those
treated with the standard PDF (74% vs 62% at 28 months,
p = 0.0032). In a multivariate Cox regression model includ-
ing age, diabetes, and gender, the survival advantage per-
sisted (relative risk of death for Balance 0.75, 95% confi-
dence interval 0.56 – 0.99, p = 0.0465). Modality technique
survival was similar in Kaplan–Meier analysis for both PDFs.
No differences were detected in peritonitis-free survival or
in peritonitis rates between the two solutions.
¤¤
¤¤
¤ Conclusion: This study, for the first time, suggests that
treatment with a novel biocompatible PDF with low GDP con-
centration and neutral pH confers a significant survival
advantage. The exact mechanisms for such a survival ad-
vantage cannot be determined from this study. The usual
criticisms of observational studies apply and the results
reported here strongly warrant the undertaking of appro-
priately designed, randomized, controlled clinical trials.
Perit Dial Int 2005; 25:248–255 www.PDIConnect.com
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The evolution of the composition of peritoneal dialy-sis fluids (PDFs) reflects our progressive under-
standing of peritoneal physiology, solute kinetics,
biocompatibility, and manufacturing processes. Normal
saline was first used clinically as a PDF in the 1920s (1),
and early formulations of PDF mimicked the physiologi-
cal electrolytic composition of blood. Except for the use
of various buffer bases throughout the years, the com-
position of PDFs remained essentially unchanged until
the past decade. In recent years, the observation that
peritoneal membrane performance and anatomy dete-
riorate over time exposed to PDFs resulted in a surge of
activity in search of biocompatible solutions (2–5).
The recently published ADEMEX study (6) and com-
mentaries arising after its publication (7) suggest that,
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to improve clinical outcomes for patients treated by con-
tinuous ambulatory peritoneal dialysis (CAPD), we have
to look beyond peritoneal solute clearance to issues of
volume management, preservation of residual renal
function (RRF), and moderation of cardiovascular risk
burden. For the latter, where chronic inflammation and
oxidative stress are known risk factors (8), it is of inter-
est to understand more fully the possible contribution
of PDF bioincompatibility to these risk factors.
Recent research has generated a large body of in vitro
and in vivo evidence associating glucose degradation
products (GDPs), pH, osmolality, and lactate with func-
tional and morphologic changes in peritoneal vessels,
mesothelial cells, interstitium, and cells associated with
host defense (9–15). The use of neutral-pH low-GPD so-
lutions has been shown to improve peritoneal cell func-
tion and viability, both of which suggest prolongation
of peritoneal membrane function and life, and better
patient outcomes (16–18). However, until now there has
been no clinical evidence that, indeed, patient outcomes
are improved with the use of such PDFs.
The present retrospective observational study com-
paring outcomes among incident CAPD patients treated
with either conventional PDFs or new pH-neutral low-
GDP solutions is the first to show a survival advantage
for patients treated with the new biocompatible PDFs.
PATIENTS AND METHODS
PATIENTS
Incident CAPD patients commencing treatment on or
after 1 January 2002 and before 1 January 2004 with
either standard PDF [stay·safe; Fresenius Medical Care
(FMC), St. Wendel, Germany] or low-GDP neutral-pH PDF
(Balance; FMC) were culled from a database of over 2000
patients treated with FMC PD products in 120 Korean di-
alysis centers. This start date was chosen because Bal-
ance was introduced commercially in Korea only in the
latter half of 2001 and it was desirable to have patients
treated with either solution from the same era. The
dataset was further confined to adult patients (age ‡ 18
years) and to those treated exclusively with CAPD (ex-
clusion of automated PD patients).
The final dataset included 1162 patients treated in 83
dialysis centers. Of the 83 centers, 25 centers contrib-
uted only stay·safe patients (n = 119) and 25 centers
contributed only Balance patients (n = 201); 33 centers
contributed both stay·safe (n = 432) and Balance pa-
tients (n = 410); 55 centers had £ 10 patients registered
in the dataset (stay·safe 98 and Balance 105); 12 cen-
ters had 11 – 20 (stay·safe 108 and Balance 73); 6 cen-
ters had 21 – 30 (stay·safe 85 and Balance 75), 5 cen-
ters had 31 – 50 (stay·safe 62 and Balance 125), and
5 centers each contributed in excess of 50 patients
(stay·safe 198 and Balance 233). These patient numbers
do not necessarily reflect the total activity or experience
of each center since the dataset includes only those pa-
tients being treated with a product supplied by FMC.
Of the 1162 patients included in the analysis, 611 pa-
tients were initiated and maintained on Balance, 376
were initiated and maintained on stay·safe, and a fur-
ther 175 commenced treatment with stay·safe and sub-
sequently were converted to Balance. None of these
patients received simultaneous treatment with other PD
solutions such as polyglucose or amino acid. The data-
base was “closed” for analysis on 31 May 2004. The pri-
mary analysis was conducted on an intent-to-treat (ITT)
basis. Thus, recorded events were ascribed to the first
treatment received by the patient (stay·safe or Balance),
irrespective of a switch from stay·safe to Balance.
Data recorded included unique patient identifiers,
patient sex and age, primary renal diagnosis, date of
enrolment, date of discharge (including death and drop-
out for any reason, including transfer to hemodialysis),
reason for dropout, and cause of death. Because the
database was created specifically to monitor patients
treated using FMC products, patients converted to a
competitor’s product were classified as dropout on the
date the patient was converted to another product. In
addition, all peritonitis episodes occurring in this pa-
tient cohort were recorded as the date of onset of the
episode. The dataset does not record laboratory data,
clearance values, or peritoneal transporter status.
PERITONEAL DIALYSIS TREATMENT
Prescription and delivery of CAPD treatment, includ-
ing the choice of PD solution (stay·safe or Balance), were
at the discretion of the patients’ treating physicians.
Likewise, decisions to discontinue CAPD, to convert to
hemodialysis, or to change the PD solution for a
competitor’s product were taken by the treating physi-
cian. The dataset does not record data indicating the
reason for the prescribers’ choices.
The standard PDF, stay·safe, is a heat-sterilized PD
fluid presented in a single compartment, double-bag
system manufactured with the PVC-free foil Biofine and
with disc-and-pin connectology as previously described
(19). The low-GDP neutral-pH PDF, Balance, uses the
same foil and connectology and is prepared in a dual-
chambered, double bag where a welded seam separates
the glucose and electrolyte component at low pH (2.8 –
3.1) from the buffer component at alkaline pH during
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sterilization. By rupturing the seal dividing the compart-
ments immediately prior to use, complete mixing of the
two solutions is achieved virtually instantaneously. The
chemical composition of the two solutions, including
concentrations of common GDPs, is shown in Table 1.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS, version
11.5 (SPSS Inc., Chicago, Illinois, USA). The unpaired
Student’s t-test was used to compare continuous nor-
mally distributed data; the chi-square test was used for
comparison of categorical variables. Patient, technique,
and peritonitis-free survivals for the two PD solutions
were analyzed and compared using the Kaplan–Meier
method and tested by log rank statistic. The Cox propor-
tional hazards model was used to adjust for significant
covariates, including the PDF used in treatment, patient
age (continuous variable), patient sex (female vs male),
and diabetic status (yes vs no). In the multivariate
model, covariates were entered using the forward con-
ditional method. In the analysis of patient survival, cen-
sored events included recovery of renal function, renal
transplantation, and dropout to hemodialysis or to a
competitor product. In the analysis of technique survival,
the measured events included conversion to hemodialy-
sis and transfer to a competitor product; all other events
were censored. All statistics were two-tailed and statis-
tical significance was defined by an alpha value less than
0.05.
RESULTS
CHARACTERISTICS OF PATIENTS AT ENROLMENT
Table 2 lists the main characteristics of the patients
allocated to the treatment PDFs on the ITT basis. For the
recorded parameters, the two groups of patients
(stay·safe and Balance) were well matched except for a
significantly older age for patients treated with stay·safe
(average difference +1.6 years, p = 0.049). The propor-
tion of patients treated with stay·safe who were older
than 60 years also exceeded that for patients treated by
Balance (47% vs 39% respectively) but this was not sta-
tistically significant (c 2 = 0.623, p = 0.419). Sex distri-
bution and distribution by cause of renal failure were
similar for the groups (Table 2).
PATIENT SWITCH FROM STAY·SAFE TO BALANCE
The number of patients that switched from stay·safe
to Balance was 175. The mean interval from start of treat-
ment to PDF switch was 9.5 ± 6.1 months. There was no
difference in sex distribution or in rate of diabetes be-
TABLE 2
Main Characteristics of the Patients Treated by Two
Peritoneal Dialysis Fluids Allocated on the
Basis of Intent-to-Treat
Balancea stay·safea
(n=611) (n=551) p Valueb
Year incidence
2002 232 (38%) 324 (59%) <0.0001
2003 379 (62%) 337 (41%)
Sex
Female 282 (46%) 240 (44%) 0.066
Male 329 (54%) 311 (56%)
Age, mean (years) 55.38±13.4 56.97±13.9 0.049
Age (category)
£ 60 372 (61%) 294 (53%) 0.419
>60 239 (39%) 257 (47%)
Diabetic status
Nondiabetic 302 (49%) 252 (46%) 0.685
Diabetic 309 (51%) 299 (54%)
a Manufactured by Fresenius Medical Care, St. Wendel,
Germany.
b p Values compare patients treated with stay·safe with those
treated with Balance. Proportions tested by chi-square and
means by Student’s t-test.
TABLE 1
Comparison of the Chemical Composition of
Two Peritoneal Dialysis Fluids (PDFs)
stay·safea Balancea,b
Sodium (mmol/L) 134 134
Calcium (mmol/L) 1.75 1.75
Magnesium (mmol/L) 0.5 0.5
Chloride (mmol/L) 103.5 101.5
Lactate (mmol/L) 35 35
Bicarbonate (mmol/L) 0 2
pH 5.5 7
Glucose (anhydrous) (g/L)c 15–42.5 15–42.5
3-deoxyglucosone ( m mol/L)c 172–324 42–60
Methylglyoxal (m mol/L)c 6–10 <1d
Acetaldehyde (m mol/L)c 152–182 <2d
Formaldehyde (m mol/L)c 7–13 <3d
a Manufactured by Fresenius Medical Care, St. Wendel,
Germany.
b After mixing.
c The lower value in the range refers to 1.5% dextrose PDF and
the higher value to 4.25% dextrose PDF.
d Below detectable limit.
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tween patients who did and patients who did not switch
(data not shown). Patients who switched were signifi-
cantly younger than non-switchers (52.3 vs 56.8 years,
p < 0.0001).
PERITONITIS RATE AND PERITONITIS-FREE SURVIVAL
For 899 of the 1162 patients included in the analysis
(77%), no peritonitis episode was reported. Of the re-
maining patients, 19% of Balance patients and 17.4% of
stay·safe patients suffered a single episode of peritoni-
tis, and 3.3% (Balance) and 5.6% (stay·safe) suffered
two or more episodes ( c 2 = 6.22, p = 0.183). Patients
treated with Balance experienced 161 episodes of peri-
tonitis yielding 7793 months of exposure (1 episode/48
months), which was identical to the rate for stay·safe
patients (164 episodes for 7875 months: 1 episode/48
months). There was no difference for the time to first
episode of peritonitis, compared using the Kaplan–Meier
method and log rank statistic (p = 0.614; Figure 1).
TECHNIQUE SURVIVAL
According to the definition of technique survival (see
Methods), 52 patients in the Balance group and 50 pa-
tients in the stay·safe group experienced a technique
failure. The causes for technique failure were change to
competitor product, 23 (stay·safe 2%, Balance 2%); con-
version to hemodialysis, 75 (stay·safe 6.9%, Balance
6.1%); and other, 4 (stay·safe 0.2%, Balance 0.5%).
None of these differences was statistically significant.
Censored events included 199 deaths (stay·safe 21.8%,
Balance 12.9%), 40 renal transplants (stay·safe 4%,
Balance 2.9%), and 11 patients who recovered renal
function (stay·safe 1.5%, Balance 0.5%). As shown in
Figure 2, there was no significant difference in time to
technique failure between the groups. Excluding conver-
sions to competitor products did not significantly alter
the results of the analysis (data not shown).
PATIENT SURVIVAL
In the ITT analysis, 79 patients treated with Balance
and 120 treated with stay·safe died. The respective mor-
tality rates were 12.2 deaths per 100 patient-years for
Balance and 18.3 deaths per 100 patient-years for
stay·safe (p < 0.004). The proportions of deaths caused
by cardiovascular disease and infection were similar for
patients treated with either PDF (data not shown). The
Kaplan–Meier plot for patient survival is shown in Fig-
ure 3. At 28 months, cumulative survival for patients
treated with Balance was 74% and 62% for stay·safe (p =
0.0032). The results of the Kaplan–Meier analyses of
patient survival differed when stratification was under-
taken. The superior survival identified for Balance failed
to reach statistical significance when patients were
stratified by age (£ 60 years, p = 0.158; >60 years, p =
0.106) and, whereas the effect of Balance was highly sig-
nificant for male patients (p = 0.018), the effect failed
to reach significance for female patients (p = 0.067). The
survival advantage for Balance was significant for non-
diabetic patients (p = 0.039) but fell just short of sig-
nificance for diabetics (p = 0.059).
Figure 1 — Kaplan–Meier survival plot of interval to first epi-
sode of peritonitis (Balance: black line; stay·safe: gray line;
both manufactured by Fresenius Medical Care, St. Wendel,
Germany). There was no significant difference in peritonitis-
free survival comparing the two peritoneal dialysis fluids (log
rank = 0.25, p value = 0.614).
Figure 2 — Kaplan–Meier plots for modality technique survival
(Balance: black line; stay·safe: gray line; both manufactured
by Fresenius Medical Care, St. Wendel, Germany). There was
no overall difference in technique survival comparing Balance
and stay·safe (log rank = 0.01, p = 0.932).
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The following covariates were entered into a Cox pro-
portional hazard regression model: age, sex, diabetic
status, and PDF used at initiation of treatment. The re-
sults of the univariate and multivariate analyses are pre-
sented in Table 3. In the univariate analysis, age and
diabetes were associated with significantly increased
relative risk (RR) of patient death, and treatment with
Balance with a reduced RR; a statistically insignificant
increased risk of death was identified for female sex. In
the multivariate model, each additional year of age in-
creased the RR of death by 6.8% (p < 0.0001), and dia-
betes was associated with a 57% increased RR of death
(p = 0.003). Treatment with Balance PDF independently
lowered the RR of death by 25% (p = 0.046).
DISCUSSION
The most remarkable finding from this retrospective
study involving over 1100 incident Korean patients
treated by CAPD for up to 30 months is the superior sur-
vival of patients treated with the PDF with lower con-
centration of GDPs and neutral pH (Balance), compared
to patients treated with a conventional PDF. Despite a
marginally signif icant dif ference in patient age
(stay·safe older than Balance, p = 0.049) and a higher
proportion of diabetics in the stay·safe group (not sig-
nificant; p = 0.685), the use of Balance remained an in-
dependent predictor of reduced RR of death in the
multivariate Cox proportional hazards model, which in-
cluded patient sex, age, and diabetic status. No differ-
ences between the two PDFs were identif ied for
technique (modality) survival or for peritonitis-free sur-
vival or peritonitis rates.
The analysis by ITT, if anything, tended to favor pa-
tients allocated to the stay·safe group. Patients who
switched from stay·safe to Balance were considerably
younger (by 4.5 years, p < 0.0001) than patients who
did not switch and there were marginally fewer diabetic
patients (50% vs 53%; not significant). As expected, this
group of patients had a significantly lower mortality rate
(7.8/100 patient-years) compared to patients treated by
either PDF and who did not switch (stay·safe 27.4 and
Balance 12.2 deaths/100 years). In a multivariate Cox
proportional hazards regression analysis using a per pro-
tocol (as treated) allocation to PDF and including age,
sex, and diabetic status as covariates, treatment with
Balance was independently associated with a 55% reduc-
tion in RR of death (p < 0.0001; data not shown).
Unfortunately, the analysis is limited by the absence
of data about factors known to affect the survival of CAPD
patients, including RRF, dialysis adequacy, and perito-
neal transport status. Furthermore, the lack of data that
would define the prescribing physicians’ reasons for pre-
scribing one or other PDF or for switching patients from
the conventional PDF to Balance necessarily raises ques-
tions of ascertainment bias (positive selection for the
Balance PDF). We believe it unlikely that one or more of
TABLE 3
Results of the Univariate and Multivariate Cox Regression Analysis of Predictors of Patient
Death Based on Intention-to-Treat Allocation to Peritoneal Dialysis Fluid (PDF)
Univariate model Multivariate model
95% confidence interval 95% confidence interval
RR Lower Upper p Value RR Lower Upper p Value
Female (vs male) 1.132 0.857 1.495 0.382 1.274 0.963 1.685 0.090
Diabetic (vs nondiabetic) 2.042 1.515 2.753 0.000 1.569 1.163 2.117 0.003
Age (each year older) 1.071 1.057 1.085 0.000 1.068 1.055 1.082 0.000
PDF (Balancea vs stay·safea) 0.654 0.492 0.869 0.003 0.748 0.562 0.995 0.046
a Manufactured by Fresenius Medical Care, St. Wendel, Germany.
Figure 3 — Kaplan–Meier plot of patient survival (Balance:
black line; stay·safe: gray line; both manufactured by Fresen-
ius Medical Care, St. Wendel, Germany). The survival of Bal-
ance patients was significantly greater than that of stay·safe
patients (log rank = 8.71, p = 0.0032).
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these factors with known relevance to patient survival
could be so differently distributed in the two treatment
groups as to explain the observed survival difference.
We recognize the possibility that physicians might se-
lect patients with an overall better prognosis when pre-
scribing a novel treatment that promises a benefit such
as prolonged technique survival. The lower age of the
patients selected to be treated with Balance would be
consistent with such bias, but we think it unlikely that
such bias would fully explain the survival advantage for
the patients treated with Balance. Furthermore, the pa-
tients analyzed by ITT as stay·safe patients included 175
patients who were converted to Balance. This group of
patients was significantly younger (and presumably at
lower risk) than the patient group treated exclusively
with Balance and would “bias” the results in favor of the
stay·safe group. The similar rates of peritonitis and the
identical technique survival rates experienced by pa-
tients treated with either PDF also argue against such a
bias. The only means of resolving these and related is-
sues is through an adequately powered, randomized,
controlled clinical trial.
Might the difference in outcomes be somehow related
to a “center” effect? Because of the distribution of pa-
tients across the 83 centers (see Methods), it was not
possible to examine for a center effect in the full Cox pro-
portional hazards model. We identified 9 centers that each
contributed in excess of 30 patients and treated patients
with both PD solutions (stay·safe 210, Balance 256). In
a separate analysis of those patients, stay·safe patients
were significantly older (56 vs 53 years, p = 0.037) and
had a slight but insignificant excess of diabetics (49.5%
vs 47.3%, p = 0.257). In this subset analysis, compara-
tive gross mortality was 17% for patients treated with
stay·safe and 7.8% for patients treated with the Balance
solution. In a Kaplan–Meier analysis, a survival advan-
tage for Balance patients at 28 months failed to reach
statistical significance (log rank = 3.42, p = 0.0645). In a
Cox regression analysis, age [RR of death for each addi-
tional year 1.05, 95% confidence interval (CI) 1.025 –
1.076] and diabetes (RR of death 1.94 vs nondiabetic,
95% CI 1.113 – 3.466) were associated with mortality but
no significant impact for the PD solution and no center
effect were identified. This negative result of the effect
of the PD solution on survival must be viewed with cau-
tion (type II error) in light of the reduced number of pa-
tients and mortal events included in the analysis.
Another possible criticism relates to whether these re-
sults can reasonably be extrapolated to other populations
of PD patients. The Korean patient population described
here is ethnically and racially homogenous. Over recent
years, Korean PD clinicians have extensively reported their
outcomes for PD in the Korean and international medical
literature (20–22). Overall, these publications do not sug-
gest that Korean patients treated with PD differ in any es-
sential respect from their counterparts treated elsewhere.
However, the hypothesis suggested by these results in
Korean patients — that the use of more biocompatible PDF
results in superior patient outcome — needs to be tested
in patients of other racial and ethnic mixes.
Any discussion of what mechanism or mechanisms
might explain superior patient survival for a PDF with
low GDP concentration and neutral pH is necessarily con-
jectural. A large amount of literature addresses experi-
mental data related to PD solutions with the chemical
characteristics of Balance. Peritoneal dialysis solutions
with low GDP concentration and neutral pH have been
identified as generally less cytotoxic for mesothelial cells
(16,17) and resident host-defense cells (14,15,23). Sev-
eral clinical studies have reported an increase in cancer
antigen 125 levels in peritoneal effluent with these so-
lutions compared to standard PDF (18,24,25). The infer-
ence is that low-GDP solutions preserve mesothelial cell
mass or cell vitality. As of now, there is no evidence that
preservation of mesothelial cell mass or homeostasis
protects patients from adverse outcomes. Peritoneal di-
alysis fluids with low GDP content and neutral pH have
also been shown to be associated with superior function
of peritoneal host-defense cells, including resident mac-
rophages and polymorphonuclear leukocytes (23). The
promise of such data is that rates of peritonitis or the
course of episodes of peritonitis would be favorably im-
pacted by the use of low-GDP solutions. Montenegro et al.
recently presented their preliminary report of lower peri-
tonitis rates with neutral pH, low GDP, bicarbonate solu-
tions (26). In the present study, we failed to observe any
difference in the rate of peritonitis.
Numerous studies, including CANUSA, have demon-
strated that survival of PD patients is highly correlated with
RRF (27–29). In the Euro Balance Trial, patients treated
with low-GDP PD solution exhibited a trend toward better
preservation of RRF (18). In the same study, patients
treated with Balance, the low-GDP solution, were found
to have lower serum concentrations of advanced glycation
end-product (AGE) markers (carboxymethyllysine and
imidazolone) than when treated with standard solution,
although the authors found no correlation between AGE
markers and RRF (18). AGEs have been extensively impli-
cated in microvascular and macrovascular disease in ure-
mic and diabetic patients, and GDPs and AGEs have been
implicated in contributing to local and systemic
microinflammation (30,31). Directly, or indirectly through
lesser induction of inflammation, a reduction in advanced
glycation might result in preservation of RRF.
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Several clinical studies have reported a reduction in
the concentration of peritoneal effluent hyaluronan
when patients are converted from conventional PDF to
low-GDP PDF (18,24), with the inference that local peri-
toneal inflammation is reduced by these solutions. As of
now, there are no reports that use of low-GDP solutions
is associated with reduction in levels of markers of sys-
temic inflammation. Like their hemodialysis counter-
parts, PD patients exhibit a chronically inflamed state,
as evidenced by elevated serum concentration of pro-
inflammatory cytokines and C-reactive protein (32–34).
Extensive epidemiological evidence both in the general
population (35) and in uremic and dialysis patients as-
sociates chronic microinflammation with mortality, as
reviewed by Arici and Walls (36). In a recent publication,
the finding of an elevated C-reactive protein concentra-
tion predicted outcome in PD patients (37). Moreover, a
state of chronic inflammation is associated with accel-
erated decline in RRF (33). In the present study, we lack
data allowing the measurement of inflammatory status,
and RRF was not monitored. In any future prospective
study seeking to examine the effect of novel low-GDP
solutions on patient outcome, inflammatory markers and
RRF should be monitored and we are aware of a proposed
randomized controlled trial to be initiated soon in Aus-
tralia and New Zealand (the balANZ Trial) that will ex-
amine these variables.
In conclusion, from this study we observe a superior
survival of patients treated with a PD solution with low
GDP content and neutral pH. As an observational study,
it has many limitations, as discussed above. However,
the magnitude of the result, the superior patient sur-
vival exper ienced by patients treated with the
biocompatible PDF, should prompt the undertaking of
appropriately designed, prospective, randomized con-
trolled studies seeking to affirm the observational re-
sults reported here.
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